Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers
- Registration Number
- NCT01776437
- Lead Sponsor
- Pfizer
- Brief Summary
This is a randomized, 2-period, 2-sequence crossover study to evaluate the effect of food on the relative bioavailability of BMN 673 during fasting and fed conditions in healthy male subjects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 18
Inclusion Criteria
- Male, between the ages of 18 and 55.
- Non-smoking for at least 1 year before Screening.
- Willing and able to provide informed consent.
- Have a BMI between 18 to 30kg/m2.
- Willing and able to comply all study procedures.
- Have adequate organ function
- Sexually active patients must be willing to use an acceptable method of contraception.
Exclusion Criteria
- History of any illness that might confound the results of the study or pose an additional risk in administering study medication to the subject.
- Current use of prescription medication or regular treatment with over-the-counter medications.
- Consumption of herbal medications or dietary supplements.
- Consumption of more that than 3 units of alcoholic beverages per day.
- Consumption of more than five 240-mL servings of coffee or other caffeinated beverage.
- History of alcohol or drug abuse or addiction within 6 months of study entry.
- Participation in a clinical Study involving administration of an investigational drug within 1 month or 5 half lives (whichever is longer).
- Donation of any blood or having had a significant loss of blood with 56 days.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Treatment A BMN 673 Period 1: fasted control → Period 2: fed control Treatment B BMN 673 Period 1: fed control → Period 2: fasted control
- Primary Outcome Measures
Name Time Method The primary outcome of this study is to evaluate the effect of food on the relative bioavailability of BMN 673. The Pharmacokinetic analyses of plasma BMN 673 concentration-time will be measured using non-compartmental methods. 4 months
- Secondary Outcome Measures
Name Time Method Assess the safety and tolerability of BMN 673 during fasting and fed conditions with the following safety assessments: adverse events, physical examination, vital signs, concomitant medications, clinical laboratory tests and ECG. 4 months
Trial Locations
- Locations (1)
Covance Clinical Research Unit Inc.
🇺🇸Evansville, Indiana, United States